Men i notene er det litt mer informasjon om avtalen. For første gang er det skrevet helt tydelig at Vaccibody skal ta kostnadene med en ny studie. Og så er det altså både en up-front del og en near-term del. De 15 millionene i near term i 2021 er det naturlig å tenke er knyttet til FPD i VB N-02. Og så er det evt. et åpent spørsmål om de 10 mill i 2022 er knyttet til ferdig innrullert eller første safety-avlesning.
"On September 29, 2020, Vaccibody entered into an exclusive worldwide license and collaboration agreement with Genentech Inc. (”Genentech”), a member of the Roche Group, for the development and commercialization of DNA-based individualized neoantigen vaccines for the treatment of cancers.
As part of the Genentech Agreement Vaccibody has granted to Genentech a license which is limited to “Collaboration Products”, i.e. any individualized Therapy DNA vaccine i) that includes a Chimera Structure within Vaccibody IP or joint IP and ii) that incorporates one or more neoantigen DNAs.
In addition to granting an exclusive license to Genentech, Vaccibody will also sponsor R&D commitments which are mainly related to the conduction of a Phase 1b Study
at Vaccibody’s sole cost and expense. Following completion of the Phase 1b Study, Genentech will have responsibility and bear all costs for clinical, regulatory, manufacturing and commercialization activities.
Under the terms of the agreement, Vaccibody will receive USD 185 million in initial upfront and USD 40 million in near-term payments. Additionally, Vaccibody will be eligible to receive up to a further USD 490 million in potential milestone payments, plus low double- digit tiered royalties on sales of commercialized products arising from the partnership.
During 2020, USD 200 million has been invoiced of which USD 196 million has been paid. The unpaid amount will be received during 2021. The remaining 25 million will be received in 2021 (USD 15 million) and 2022 (USD 10 million)."
